Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles
Advanced Science · 2023
DOI: 10.1002/advs.202301377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Dana Tarab-Ravski und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Precision NanoMedicine, The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv Univer…. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Multiple myeloma (MM) is a cancer of differentiated plasma cells that occurs in the bone marrow (BM). Despite the recent advancements in drug development, most patients with MM eventually relapse and the disease remains incurable. RNA therapy delivered via lipid nanoparticles (LNPs) has the potential to be a promising cancer treatment, however, its clinical implementation is limited due to inefficient delivery to non‐hepatic tissues. Here, targeted (t)LNPs designed for delivery of RNA payload to MM cells are presented. The tLNPs consist of a novel ionizable lipid and are coated with an anti‐CD38 antibody ( α CD38‐tLNPs). To explore their therapeutic potential, it is demonstrated that LNPs encapsulating small interference RNA (siRNA) against cytoskeleton‐associated protein 5 (CKAP5) lead to a ≈90% decrease in cell viability of MM cells in vitro. Next, a new xenograft MM mouse model is employed, which clinically resembles the human disease and demonstrates efficient homing of MM cells to the BM. Specific delivery of α CD38‐tLNPs to BM‐residing and disseminated MM cells and the improvement in therapeutic outcome of MM‐bearing mice treated with α CD38‐tLNPs‐siRNA‐CKAP5 are shown. These results underscore the potential of RNA therapeutics for treatment of MM and the importance of developing effective targeted delivery systems and reliable preclinical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Precision NanoMedicine, The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 69978, Israel.
- Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv, 69978, Israel.
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 69978, Israel.
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv, 69978, Israel.
- Department of Pharmacology, Weil Cornell Graduate School for Biomedical Sciences, New York, NY, 10065, USA.
- Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
ORCID-Profile: Dan Peer
Förderung
- NCI NIH HHS
Zitieren
APA
Tarab-Ravski, D., Hazan-Halevy, I., Goldsmith, M., Stotsky-Oterin, L., Breier, D., Naidu, G. S., Aitha, A., Diesendruck, Y., Ng, B. D., Barsheshet, H., Berger, T., Vaxman, I., Raanani, P., & Peer, D. (2023). Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles. Advanced Science. https://doi.org/10.1002/advs.202301377
Vancouver
Tarab-Ravski D, Hazan-Halevy I, Goldsmith M, Stotsky-Oterin L, Breier D, Naidu GS, et al. Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles. Advanced Science. 2023. doi:10.1002/advs.202301377
BibTeX
@article{TarabRavski2023,
author = {Tarab-Ravski, Dana and Hazan-Halevy, Inbal and Goldsmith, Meir and Stotsky-Oterin, Lior and Breier, Dor and Naidu, Gonna Somu and Aitha, Anjaiah and Diesendruck, Yael and Ng, Brandon D and Barsheshet, Hagit and Berger, Tamar and Vaxman, Iuliana and Raanani, Pia and Peer, Dan},
title = {Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202301377}
}
EUVIMED